JP2018193386A5 - - Google Patents

Download PDF

Info

Publication number
JP2018193386A5
JP2018193386A5 JP2018137861A JP2018137861A JP2018193386A5 JP 2018193386 A5 JP2018193386 A5 JP 2018193386A5 JP 2018137861 A JP2018137861 A JP 2018137861A JP 2018137861 A JP2018137861 A JP 2018137861A JP 2018193386 A5 JP2018193386 A5 JP 2018193386A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
possessed
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018137861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018193386A (ja
JP7012360B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018193386A publication Critical patent/JP2018193386A/ja
Publication of JP2018193386A5 publication Critical patent/JP2018193386A5/ja
Application granted granted Critical
Publication of JP7012360B2 publication Critical patent/JP7012360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018137861A 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体 Active JP7012360B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013039625 2013-02-28
JP2013039625 2013-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015503025A Division JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Publications (3)

Publication Number Publication Date
JP2018193386A JP2018193386A (ja) 2018-12-06
JP2018193386A5 true JP2018193386A5 (cg-RX-API-DMAC7.html) 2019-03-14
JP7012360B2 JP7012360B2 (ja) 2022-02-14

Family

ID=51428352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Country Status (5)

Country Link
US (1) US9429584B2 (cg-RX-API-DMAC7.html)
EP (2) EP3339327A3 (cg-RX-API-DMAC7.html)
JP (2) JP6490574B2 (cg-RX-API-DMAC7.html)
ES (1) ES2673583T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014133093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167227A1 (ja) * 2015-04-13 2016-10-20 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
JP2018527350A (ja) 2015-09-01 2018-09-20 イミュンワーク インク.Immunwork Inc. 血餅形成の予防及び/又は血栓症の治療のための分子構築物
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
US10736976B2 (en) * 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
BR112019022643A2 (pt) * 2017-05-02 2020-05-19 Nat Cancer Center Japan conjugado de fármaco-anticorpo anti-fibrina insolúvel clivável por plasmina
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトMUC1抗体Fabフラグメント、ペプチドリンカー及び/又は配位子を含む複合体
JP2022501428A (ja) * 2018-09-17 2022-01-06 アイカーン スクール オブ メディスン アット マウント シナイ 抗lilrb2抗体およびその使用の方法
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
US20230132177A1 (en) * 2020-03-31 2023-04-27 National Cancer Center Fibrin-binding antibody and pharmaceutical composition containing antibody
AU2021246398A1 (en) * 2020-03-31 2022-11-03 National Cancer Center Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein
EP3916009B1 (en) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Recombinant proteins based on fibrinogen
EP4506458A1 (en) 2022-04-08 2025-02-12 RIN Institute Inc. Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein
CN118240085B (zh) * 2022-10-08 2025-05-09 东莞市朋志生物科技有限公司 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH11206387A (ja) 1991-08-28 1999-08-03 Genpharm Internatl Inc 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JPH08301900A (ja) 1995-04-28 1996-11-19 Shima Kenkyusho:Kk 可溶性フィブリン複合体に対するモノクローナル抗体
KR19990008197A (ko) 1995-04-28 1999-01-25 레이몬드 엠. 위티 면역화된 제노마우스 유래의 인체 항체
JPH09104700A (ja) 1995-10-09 1997-04-22 Bio Rinkusu Kk 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法
JP2001354700A (ja) 2000-06-12 2001-12-25 Bio Links Kk モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
US7087724B2 (en) 2001-06-26 2006-08-08 Agen Biomedical Ltd Carrier molecules
JP5222521B2 (ja) 2004-12-28 2013-06-26 積水メディカル株式会社 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法
CN101087877B (zh) 2004-12-28 2012-08-08 第一化学药品株式会社 抗人可溶性血纤蛋白单克隆抗体及使用该抗体的免疫学测定方法
KR101591223B1 (ko) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
EP2502999A3 (en) * 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2008096760A1 (ja) 2007-02-05 2008-08-14 Osaka University 新規ヘキサトリエン-β-カルボニル化合物
US20110287036A1 (en) 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
JP5805363B2 (ja) * 2009-06-26 2015-11-04 和興フィルタテクノロジー株式会社 可溶性凝集体、免疫寛容誘導剤及びその製造方法
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Similar Documents

Publication Publication Date Title
JP2018193386A5 (cg-RX-API-DMAC7.html)
JP2020022464A5 (cg-RX-API-DMAC7.html)
JP2019110906A5 (cg-RX-API-DMAC7.html)
JP2024020298A5 (cg-RX-API-DMAC7.html)
JP2017176174A5 (cg-RX-API-DMAC7.html)
JP2020513786A5 (cg-RX-API-DMAC7.html)
CN113316591A (zh) Cd73抗体及其制备方法和应用
JP2019107018A5 (cg-RX-API-DMAC7.html)
JP2017113019A5 (cg-RX-API-DMAC7.html)
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
JP2017523786A5 (cg-RX-API-DMAC7.html)
JP2015514110A5 (cg-RX-API-DMAC7.html)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2013545734A5 (cg-RX-API-DMAC7.html)
JP2018508483A5 (cg-RX-API-DMAC7.html)
JP2018198596A5 (cg-RX-API-DMAC7.html)
JP2016116536A5 (cg-RX-API-DMAC7.html)
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
JP2010506596A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JP2018537962A5 (cg-RX-API-DMAC7.html)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2017500018A5 (cg-RX-API-DMAC7.html)
RU2020142534A (ru) Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство